Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Crestor Promotions Tee Off With PGA

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsorship of weekly golf events begins the weekend of March 6-7. A "reminder" ad for the statin is currently airing on television.

You may also be interested in...



Crestor Promotions “Should Not Overly Emphasize” 10 Mg Given 5 Mg Efficacy – FDA

Medical reviewers initially recommended approval of doses “well below” AstraZeneca’s proposed 10 mg starting dose. Final labeling includes standard start dose of 10 mg, with a 5 mg dose recommended for patients who do not require large LDL reductions or are likely to experience myopathy.

Crestor Promotions “Should Not Overly Emphasize” 10 Mg Given 5 Mg Efficacy – FDA

Medical reviewers initially recommended approval of doses “well below” AstraZeneca’s proposed 10 mg starting dose. Final labeling includes standard start dose of 10 mg, with a 5 mg dose recommended for patients who do not require large LDL reductions or are likely to experience myopathy.

AstraZeneca Crestor Should Be Withdrawn For Safety Reasons, Public Citizen Says

Petition cites 22 cases of "serious" post-marketing events, including rhabdomyolysis, kidney problems and bleeding, in the U.S., U.K. and Canada.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel